ArticleNanomedicine (London, England)2025
Preparation of surface-modified PLGA nanoparticles containing carbon quantum dots: insights from C6 cell line assays.
Article in Nanomedicine (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Carbon Nanomaterials in Biomedicine: Opportunities and Toxicological Concerns.International journal of nanomedicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsIn this study, carbon quantum dot (CQD)-loaded poly(lactic-co-glycolic acid) (PLGA) nanoparticles (NPs) were prepared, and their surfaces were modified with tween 20, tween 80, poloxamer 188, or poloxamer 407. The physicochemical properties, cytotoxicity, and cellular uptake of the NPs were subsequently evaluated using the C6 glioblastoma cell line. MATERIALS &
methodsThe NPs were prepared via the nanoprecipitation method, and surface modifications were achieved through physical adsorption. The physicochemical characteristics of the NPs including mean diameter, zeta potential, and in vitro release of CQDs, were assessed. Hemolysis and in vitro studies, including MTT assay, apoptosis/necrosis assay, and cellular uptake, were conducted.
resultsPoloxamer-coated NPs demonstrated a more sustained release of CQDs compared to tween-coated NPs. Hemolysis and cytotoxicity were concentration-dependent, with poloxamer-coated NPs exhibiting lower hemolysis at 2 mg/mL and reduced cytotoxicity at higher concentrations. All formulations were effectively internalized by C6 cells, and poloxamer 407-coated NPs showed the lowest rate of necrosis.
conclusionsPoloxamer-coated NPs exhibited favorable characteristics, including sustained release, lower toxicity, and enhanced cellular uptake. These findings support their potential as effective surface modifiers in the development of multifunctional nanocarriers for brain-targeted drug delivery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.